Tetraspanin (TSP-17) Protects Dopaminergic Neurons against 6-OHDA-Induced Neurodegeneration in

English version České info

Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons. While hereditary forms are known, most cases are attributable to a combination of genetic and environmental risk factors. In PD models, dopaminergic neurodegeneration can be triggered by neurotoxins such as 6-hydroxydopamine (6-OHDA). This drug, which is taken up by the presynaptic dopamine reuptake transporter (DAT-1), also causes the selective death of C. elegans dopaminergic neurons. We found that TSP-17, a member of the tetraspanin family of membrane proteins, protects dopaminergic neurons from 6-OHDA-induced degeneration. We provide evidence that TSP-17 inhibits the C. elegans dopamine transporter DAT-1, leading to increased neuronal 6-OHDA uptake in tsp-17 mutants. TSP-17 also protects against toxicity conferred by excessive intracellular dopamine. TSP-17 interacts with the DOP-2 dopamine receptor, possibly as part of a pathway that negatively regulates DAT-1. tsp-17 mutants have subtle behavioral phenotypes that are partly conferred by aberrant dopamine signaling. In summary, we have used C. elegans genetics to model key aspects of PD.

Vyšlo v časopise: Tetraspanin (TSP-17) Protects Dopaminergic Neurons against 6-OHDA-Induced Neurodegeneration in. PLoS Genet 10(12): e32767. doi:10.1371/journal.pgen.1004767
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1004767

Souhrn

Zdroje

1. CalneDB, LangstonJW (1983) Aetiology of Parkinson's disease. Lancet 2: 1457–1459.

2. ZigmondMJ, BurkeRE (2002) pathophysiology of parkinson's disease. Fifth generation of progess American college of Neuropsychopharmacology Williams and Wilkens 1781–1794.

3. NassR, HallDH, MillerDM3rd, BlakelyRD (2002) Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America 99: 3264–3269.

4. NassR, BlakelyRD (2003) The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration. Annual review of pharmacology and toxicology 43: 521–544.

5. ChaseTN (1997) A gene for Parkinson disease. Archives of neurology 54: 1156–1157.

6. LaiCH, ChouCY, Ch'angLY, LiuCS, LinW (2000) Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. Genome research 10: 703–713.

7. KleinC, WestenbergerA (2012) Genetics of Parkinson's disease. Cold Spring Harbor perspectives in medicine 2: a008888.

8. LangstonJW, BallardP, TetrudJW, IrwinI (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980.

9. PriyadarshiA, KhuderSA, SchaubEA, PriyadarshiSS (2001) Environmental risk factors and Parkinson's disease: a metaanalysis. Environmental research 86: 122–127.

10. TiptonKF, SingerTP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. Journal of neurochemistry 61: 1191–1206.

11. GlinkaY, GassenM, YoudimMB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. Journal of neural transmission Supplementum 50: 55–66.

12. KostrzewaRM, JacobowitzDM (1974) Pharmacological actions of 6-hydroxydopamine. Pharmacological reviews 26: 199–288.

13. AndrewR, WatsonDG, BestSA, MidgleyJM, WenlongH, et al. (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochemical research 18: 1175–1177.

14. TieuK (2011) A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harbor perspectives in medicine 1: a009316.

15. FahnS, CohenG (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Annals of neurology 32: 804–812.

16. BoveJ, PerierC (2012) Neurotoxin-based models of Parkinson's disease. Neuroscience 211: 51–76.

17. BirkmayerW, HornykiewiczO (1998) The effect of l-3,4-dihydroxyphenylalanine ( = DOPA) on akinesia in parkinsonism. Parkinsonism & related disorders 4: 59–60.

18. CotziasGC, PapavasiliouPS, GelleneR (1969) Modification of Parkinsonism–chronic treatment with L-dopa. The New England journal of medicine 280: 337–345.

19. FahnS (1999) Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Archives of neurology 56: 529–535.

20. WhiteJG, SouthgateE, ThomsonJN, BrennerS (1986) The structure of the nervous system of the nematode Caenorhabditis elegans. Philosophical transactions of the Royal Society of London Series B, Biological sciences 314: 1–340.

21. BrennerS (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71–94.

22. SulstonJ, DewM, BrennerS (1975) Dopaminergic neurons in the nematode Caenorhabditis elegans. The Journal of comparative neurology 163: 215–226.

23. TothML, SimonP, KovacsAL, VellaiT (2007) Influence of autophagy genes on ion-channel-dependent neuronal degeneration in Caenorhabditis elegans. Journal of cell science 120: 1134–1141.

24. ChenN, ReithME (2004) Interaction between dopamine and its transporter: role of intracellular sodium ions and membrane potential. Journal of neurochemistry 89: 750–765.

25. LeeFJ, PeiL, MoszczynskaA, VukusicB, FletcherPJ, et al. (2007) Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. The EMBO journal 26: 2127–2136.

26. MoszczynskaA, SalehJ, ZhangH, VukusicB, LeeFJ, et al. (2007) Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity. Journal of molecular neuroscience: MN 32: 217–227.

27. LeeFJ, LiuF, PristupaZB, NiznikHB (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 15: 916–926.

28. ChangMY, LeeSH, KimJH, LeeKH, KimYS, et al. (2001) Protein kinase C-mediated functional regulation of dopamine transporter is not achieved by direct phosphorylation of the dopamine transporter protein. Journal of neurochemistry 77: 754–761.

29. ValloneD, PicettiR, BorrelliE (2000) Structure and function of dopamine receptors. Neuroscience and biobehavioral reviews 24: 125–132.

30. MissaleC, NashSR, RobinsonSW, JaberM, CaronMG (1998) Dopamine receptors: from structure to function. Physiological reviews 78: 189–225.

31. SokoloffP, GirosB, MartresMP, BouthenetML, SchwartzJC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151.

32. BeaulieuJM, GainetdinovRR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacological reviews 63: 182–217.

33. AllenAT, MaherKN, WaniKA, BettsKE, ChaseDL (2011) Coexpressed D1- and D2-like dopamine receptors antagonistically modulate acetylcholine release in Caenorhabditis elegans. Genetics 188: 579–590.

34. ZhouQY, PalmiterRD (1995) Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83: 1197–1209.

35. SzczypkaMS, RaineyMA, PalmiterRD (2000) Dopamine is required for hyperphagia in Lep(ob/ob) mice. Nature genetics 25: 102–104.

36. SawinER, RanganathanR, HorvitzHR (2000) C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 26: 619–631.

37. McDonaldPW, HardieSL, JessenTN, CarvelliL, MatthiesDS, et al. (2007) Vigorous motor activity in Caenorhabditis elegans requires efficient clearance of dopamine mediated by synaptic localization of the dopamine transporter DAT-1. The Journal of neuroscience: the official journal of the Society for Neuroscience 27: 14216–14227.

38. ThompsonO, EdgleyM, StrasbourgerP, FlibotteS, EwingB, et al. (2013) The million mutation project: a new approach to genetics in Caenorhabditis elegans. Genome research 23: 1749–1762.

39. BoucheixC, BenoitP, FrachetP, BillardM, WorthingtonRE, et al. (1991) Molecular cloning of the CD9 antigen. A new family of cell surface proteins. The Journal of biological chemistry 266: 117–122.

40. BoucheixC, DucGH, JasminC, RubinsteinE (2001) Tetraspanins and malignancy. Expert reviews in molecular medicine 2001: 1–17.

41. BoucheixC, RubinsteinE (2001) Tetraspanins. Cellular and molecular life sciences: CMLS 58: 1189–1205.

42. RubinsteinE (2011) The complexity of tetraspanins. Biochemical Society transactions 39: 501–505.

43. DunnCD, SulisML, FerrandoAA, GreenwaldI (2010) A conserved tetraspanin subfamily promotes Notch signaling in Caenorhabditis elegans and in human cells. Proceedings of the National Academy of Sciences of the United States of America 107: 5907–5912.

44. MoribeH, YochemJ, YamadaH, TabuseY, FujimotoT, et al. (2004) Tetraspanin protein (TSP-15) is required for epidermal integrity in Caenorhabditis elegans. Journal of cell science 117: 5209–5220.

45. Garcia-EspanaA, ChungPJ, SarkarIN, StinerE, SunTT, et al. (2008) Appearance of new tetraspanin genes during vertebrate evolution. Genomics 91: 326–334.

46. CaoS, GelwixCC, CaldwellKA, CaldwellGA (2005) Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. The Journal of neuroscience: the official journal of the Society for Neuroscience 25: 3801–3812.

47. JayanthiLD, ApparsundaramS, MaloneMD, WardE, MillerDM, et al. (1998) The Caenorhabditis elegans gene T23G5.5 encodes an antidepressant- and cocaine-sensitive dopamine transporter. Molecular pharmacology 54: 601–609.

48. StrangeK, ChristensenM, MorrisonR (2007) Primary culture of Caenorhabditis elegans developing embryo cells for electrophysiological, cell biological and molecular studies. Nat Protoc 2: 1003–1012.

49. CarvelliL, McDonaldPW, BlakelyRD, DefeliceLJ (2004) Dopamine transporters depolarize neurons by a channel mechanism. Proceedings of the National Academy of Sciences of the United States of America 101: 16046–16051.

50. CassWA, GerhardtGA (1994) Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake. Neuroscience letters 176: 259–263.

51. BolanEA, KivellB, JaligamV, OzM, JayanthiLD, et al. (2007) D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Molecular pharmacology 71: 1222–1232.

52. ThaminyS, MillerJ, StagljarI (2004) The split-ubiquitin membrane-based yeast two-hybrid system. Methods Mol Biol 261: 297–312.

53. RubinsteinE, Le NaourF, Lagaudriere-GesbertC, BillardM, ConjeaudH, et al. (1996) CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. European journal of immunology 26: 2657–2665.

54. CharrinS, le NaourF, SilvieO, MilhietPE, BoucheixC, et al. (2009) Lateral organization of membrane proteins: tetraspanins spin their web. The Biochemical journal 420: 133–154.

55. MoribeH, KonakawaR, KogaD, UshikiT, NakamuraK, et al. (2012) Tetraspanin is required for generation of reactive oxygen species by the dual oxidase system in Caenorhabditis elegans. PLoS genetics 8: e1002957.

56. SeemanP (2010) Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 4: 56–73.

57. SeemanP (2011) All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 17: 118–132.

58. RangHP, DaleMM, RitterJM, FlowerRJ (2007) Antipsychotics drugs. Rang and Dale's Pharmacology 545–556.

59. GirosB, JaberM, JonesSR, WightmanRM, CaronMG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606–612.

60. UhlGR (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Annals of neurology 43: 555–560.

61. GainetdinovRR, JonesSR, FumagalliF, WightmanRM, CaronMG (1998) Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev 26: 148–153.

62. FerrisMJ, CalipariES, YorgasonJT, JonesSR (2013) Examining the complex regulation and drug-induced plasticity of dopamine release and uptake using voltammetry in brain slices. ACS Chem Neurosci 4: 693–703.

63. CalipariES, FerrisMJ, SalahpourA, CaronMG, JonesSR (2013) Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun 4: 2720.

64. JellingerK, LinertL, KienzlE, HerlingerE, YoudimMB (1995) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. Journal of neural transmission Supplementum 46: 297–314.

65. LaVoieMJ, HastingsTG (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. The Journal of neuroscience: the official journal of the Society for Neuroscience 19: 1484–1491.

66. SantiagoM, MatarredonaER, GraneroL, CanoJ, MachadoA (2000) Neurotoxic relationship between dopamine and iron in the striatal dopaminergic nerve terminals. Brain research 858: 26–32.

67. MaharajH, Sukhdev MaharajD, ScheepersM, MokokongR, DayaS (2005) l-DOPA administration enhances 6-hydroxydopamine generation. Brain research 1063: 180–186.

68. GalvinJE (2006) Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol 112: 115–126.

69. DavisMW, HammarlundM, HarrachT, HullettP, OlsenS, et al. (2005) Rapid single nucleotide polymorphism mapping in C. elegans. BMC Genomics 6: 118.

70. ChaseDL, PepperJS, KoelleMR (2004) Mechanism of extrasynaptic dopamine signaling in Caenorhabditis elegans. Nature neuroscience 7: 1096–1103.